Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2021-3039
Abstract: Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase,… read more here.
Keywords: leukemia; lineage; tak 659; syk flt3 ... See more keywords